{"altmetric_id":14135045,"counts":{"readers":{"mendeley":4,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["the_asco_post"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4e83cf058f610002280","authors":["F. Barlesi","M. Steins","L. Horn","N. Ready","E. Felip","H. Borghaei","D.R. Spigel","O. Arrieta","S.J. Antonia","J. Fayette","N. Rizvi","L. Crin\u00f2","M. Reck","W.E. Eberhardt","M. Hellmann","W.J. Geese","A. Li","D. Healey","J.R. Brahmer","L. Paz-Ares"],"doi":"10.1093\/annonc\/mdw383.15","first_seen_on":"2016-11-28T17:31:41+00:00","issns":["1569-8041"],"journal":"Annals of Oncology","last_mentioned_on":1480354237,"links":["https:\/\/annonc.oxfordjournals.org\/content\/27\/suppl_6\/1215PD.full?sid=98bdbe48-2568-41db-ac73-43af1ffffbbd"],"pdf_url":"http:\/\/annonc.oxfordjournals.org\/content\/27\/suppl_6\/1215PD.full.pdf","pubdate":"2016-10-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"title":"Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/longterm-outcomes-nivolumab-nivo-vs-docetaxel-doc-patients-pts-advanced-adv-nsclc-checkmate-017-chec"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7820779,"mean":6.6320512728979,"rank":1079990,"this_scored_higher_than_pct":85,"this_scored_higher_than":6670652,"rank_type":"exact","sample_size":7820779,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":250437,"mean":12.197177107125,"rank":51594,"this_scored_higher_than_pct":77,"this_scored_higher_than":195262,"rank_type":"exact","sample_size":250437,"percentile":77},"this_journal":{"total_number_of_other_articles":3476,"mean":9.1359551079137,"rank":721,"this_scored_higher_than_pct":76,"this_scored_higher_than":2676,"rank_type":"exact","sample_size":3476,"percentile":76},"similar_age_this_journal_3m":{"total_number_of_other_articles":111,"mean":9.6535454545455,"rank":48,"this_scored_higher_than_pct":51,"this_scored_higher_than":57,"rank_type":"exact","sample_size":111,"percentile":51}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Ph. D. Student":2,"Student  > Master":1,"Other":1},"by_discipline":{"Medicine and Dentistry":3,"Agricultural and Biological Sciences":1}}},"geo":{"mendeley":{"US":1}}},"posts":{"news":[{"title":"Numerous ESMO Presentations Focused on Anti\u2013PD-1 Therapy in Lung Cancer and Melanoma","url":"http:\/\/ct.moreover.com\/?a=28752056051&p=1pl&v=1&x=X6Ag9d4jKMAmiwGg6ht_yg","license":"public","citation_ids":[14135042,14135044,14135045,14113861],"posted_on":"2016-11-28T17:30:37+00:00","summary":"The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti\u2013programmed cell death protein 1 (PD-1) antibodies in non\u2013small cell lung cancer and melanoma, where they have clearly changed the treatment\u2026","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}]}}